The use of direct‐acting oral anticoagulants (DOACs) has increased secondary to the
mounting evidence for comparable efficacy and potentially superior safety to vitamin K …

The safety and efficacy of direct‐acting oral anticoagulants (DOACs) and reversal strategies
are not well established in the solid organ transplant population. This was a survey of …

Purpose The use of direct oral anticoagulants (DOACs) has not been fully adopted by the
solid organ transplant (SOT) community due to several transplant-specific factors including …

For more than 60 years, warfarin was the only oral anticoagulation agent available for use in
the United States. In many recent clinical trials, several direct oral anticoagulants (DOAC s) …

Background The purpose of this study was to evaluate outcomes of bleeding and thrombosis
resulting from the use of direct oral anticoagulants (DOACs) in a large cohort of solid organ …

The safety of direct oral anticoagulants (DOACs) in patients after solid organ transplantation
(SOT) is not well defined. This study aimed at describing the safety and efficacy of DOACs in …

Despite the increased use, comparative safety and efficacy of direct‐acting oral
anticoagulants (DOACs) against warfarin have not been well studied in kidney transplant …

There is limited evidence comparing direct oral anticoagulants (DOACs) and warfarin in
solid organ transplant (SOT) recipients. We performed a pooled analysis to study the safety …

Background. Oral anticoagulation therapy is frequently prescribed to kidney transplant
recipients (KTRs) for prevention and treatment of thrombotic events. Over the past 10 y …

Introduction: There is a high incidence of venous thromboembolism (VTE) in solid organ
transplant recipients. The safety and efficacy of direct-acting oral anticoagulants (DOAC) …